Clinical trial results for retatrutide have exceeded even the high expectations set by tirzepatide, with Phase 2 data published in the New England Journal of Medicine in 2023 demonstrating weight loss approaching 24-25% of baseline body weight over 48 weeks in some dose groups - weight reductions comparable to those achieved with bariatric surgery and substantially exceeding pharmacological obesity treatments available just a few years ago
The effects of l-Carnitine supplementation on inflammatory markers, clinical status, and 28 days mortality in critically ill patients: a double-blind, randomized, placebo-controlled trial
Bioavailability of calcium from tofu vs
Some prescription pain medicines, such as opioids, may cause constipation
Conclusion As a starting point to inform deeper investigations into real-world variation and patient profiles for responsiveness to therapies, our research bridges the gap between clinical trials and GLP-1 use in the real world, where a broader, more diverse population is using GLP-1s in a variety of settings and personal contexts
References: Aman S et al (2021): Management of Organophosphorus Poisoning: Standard Treatment and Beyond
